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PU.1 is an ETS-family transcription factor that plays a broad range of roles in
hematopoiesis. A direct regulator of myeloid, dendritic-cell, and B cell functional
programs, and a well-known antagonist of terminal erythroid cell differentiation, it is also
expressed in the earliest stages of T-cell development of each cohort of intrathymic
pro-T cells. Its expression in this context appears to give T-cell precursors initial, transient
access to myeloid and dendritic cell developmental competence and therefore to
represent a source of antagonism or delay of T-cell lineage commitment. However, it has
remained uncertain until recently why T-cell development is also intensely dependent
upon PU.1. Here, we review recent work that sheds light on the molecular biology of
PU.1 action across the genome in pro-T cells and identifies the genes that depend on
PU.1 for their correct regulation. This work indicates modes of chromatin engagement,
pioneering, and cofactor recruitment (“coregulator theft”) by PU.1 as well as gene
network interactions that not only affect specific target genes but also have system-wide
regulatory consequences, amplifying the impact of PU.1 beyond its own direct binding
targets. The genes directly regulated by PU.1 also suggest a far-reaching transformation
of cell biology and signaling potential between the early stages of T-cell development
when PU.1 is expressed and when it is silenced. These cell-biological functions can be
important to distinguish fetal from adult T-cell development and have the potential to
illuminate aspects of thymic function that have so far remained the most mysterious.
Keywords: transcription factor, developmental gene regulation, chromatin, T lymphocyte development, thymus,
gene network, cell signaling, hematopoiesis
INTRODUCTION
PU.1 Expression in Precursors of T Cells
PU.1, encoded by the Spi1 gene, is an ETS-family transcription factor with multiple roles in
hematopoiesis. It is a lineage-specifying transcription factor that positively regulates many genes
in the macrophage, granulocyte, dendritic-cell and B-cell lineages. Expressed at highest levels in
monocytes/macrophages, at low or moderate levels in B cells, and transiently in early erythroid
precursors, its action is also important or indispensable for sustained generation of all known
hematopoietic precursors that have lymphoid developmental potentials (1–9). Thus, B, NK, and
T cell development are all affected by defects in PU.1 activity, despite partial complementation by
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the related factor SpiB that is also activated in B-lineage
precursors. Much is known about how PU.1 finds and binds
to its sites in the DNA, typically (A/G)AGGAAGTG motifs
[e.g., (10, 11)], and it is known to be able to bind either as a
pioneer factor which displaces nucleosomes to open sites for
other factors (12), or as a collaboration-dependent partner in
binding complexes, either with activation-dependent factors like
NF-κB or with lineage-defining partners like C/EBPα (or β) or
IRF4/8 (13–15) [reviewed by (16–18)].
In myeloid, dendritic, and B lineage cells, PU.1 is a major
contributor to the positive regulation of genes that establish
lineage-specific identity (4, 17, 19). At the same time, PU.1
can work in an all-or-none gene network switch through
mutual antagonism with GATA-1 (20–24), which has been much
discussed as a possible mechanism for the irreversibility of
erythro-myeloid lineage commitment [(25–29); but also see (30,
31)]. Nevertheless, the developmental scope of PU.1 activity
is surprisingly broad, and one of its unexpected domains
of action is in the early stages of T-cell development, in
both the fetal and the postnatal mammalian thymus. To
examine what it does in pro-T cells, this review focuses on
recent data based on mouse T-cell development, mostly as it
occurs in the postnatal thymus or from late fetal progenitors.
The final section places these mechanisms in the context of
the variants of T-cell development that characterize different
ontogenic stages.
Most mature T cells do not express any detectable PU.1
protein or Spi1 transcripts at all, and the T-cell developmental
gene network sharply downregulates Spi1 in precursors of
αβ T cells before the expression of rearranged Tcrb genes,
i.e., before any TCR-dependent steps of T cell development.
However, the precursors that give rise to committed T cells
express PU.1 at both RNA and protein levels for multiple cell
divisions after these cells begin to differentiate in the thymus
(32, 33). A summary of early T-cell developmental stages,
is shown in Figure 1, with the approximate pattern of PU.1
expression marked. The downregulation of PU.1 occurs during
the transition to commitment, between the DN2 (DN=double
negative for CD4 and CD8, and Kit+ CD44+ CD25+) and
DN3 (DN, and Kitlow CD44low CD25+) stages. This expression
timing relative to other developmentally regulated transcription
factors is conserved between human and mouse (35, 36), and
as in mouse (37), the downregulation of PU.1 is important to
avoid malignancy in human T cells: a specifically aggressive
class of human T-acute lymphoblastic leukemias results from
translocations that promote abnormally sustained and elevated
PU.1 expression (38). In the mouse, where lineage commitment
has been studied in depth, there is good agreement between
the cells’ natural loss of access to the dendritic cell and
granulocyte programs, on the one hand, and the timing of PU.1
downregulation, on the other hand (33, 39–42). This is part of a
general downregulation of stem/progenitor associated regulatory
genes (“phase 1 genes”) (34, 43) and a major reorganization
of active chromatin and chromatin interactions, genome-wide,
that occurs during this transition (44). One important question
is what role PU.1 itself may have in controlling the onset of
this transformation.
FIGURE 1 | Schematic of T-cell development in the thymus. Major landmarks
for T cell developmental stages are CD4 and CD8. CD4− CD8−: “DN”; CD4+
CD8+: “DP,” CD4+ CD8−: “CD4SP”; CD4− CD8+: “CD8SP.” All events
described in this review occur within the DN stages, which are divided by other
markers. ETP: Kit++ CD44+ CD25−; DN2a: Kit++ CD44+ CD25+; DN2b:
Kit+ CD44+ CD25+; DN3a: Kit− CD44− CD25+ CD28−; DN3b: Kit−
CD44− CD25+ CD28+; DN4: Kit− CD44− CD25− CD28+. Stages up
through DN3a do not depend on T-cell receptor gene rearrangement status
and are called “Pro-T cells.” Many cell cycles occur between the ETP stage
and commitment, more in post-natal T cell development and fewer in fetal
T-cell development. The trends in PU.1 expression, the timing of intrinsic cell
commitment to the T-cell lineage, and the stages that depend on Notch
signaling from the thymic microenvironment are shown. Gray or blue regions
depict thymic cortex. Lighter region depicts thymic medulla, where final
maturation of developing T cells takes place. CD4SP: maturing T helper cells.
CD8SP: maturing T cytotoxic cells. Treg: thymically derived regulatory T cells.
iNKT: Natural Killer T cells with invariant T cell receptors [Schematic adapted
from Rothenberg et al. (34)].
PU.1 as an Obstacle to T-Cell Lineage
Commitment
The particular interest in PU.1 itself emerged from the hypothesis
that it could well be responsible for maintaining the “bridge”
to myeloid and dendritic alternative fates before commitment,
because of its known roles in many of these alternatives (and in
B cells) but not in T cells (45). This hypothesis was supported by
the finding that re-expression of PU.1 after T-cell commitment
turns on myeloid genes and readily transforms later pro-T cells
into dendritic cells, macrophages, or promyelocytic-like cells
(46–50). There is a very close relationship between the cells that
naturally express PU.1 in the thymus and those that readily
exhibit myeloid or dendritic potential in a variety of permissive
cell transfer models, in vivo or in vitro. Whereas ETP and DN2
cells can generate myeloid cells if removed from the thymus, pro-
T cells that have differentiated past the stage of PU.1 expression
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in the thymus (i.e., from the DN2 stage to the DN3 stage or
later) do not make myeloid cells under these conditions, and
this difference between stages up to DN2 and stages from DN3
onward has been a highly consistent observation (33, 40, 41,
51–56). Why, then, do PU.1-expressing early T cell precursors
within the thymus almost all go on to produce T cells, not
myeloid cells, under normal in vivo conditions (57)? A potential
explanation was provided by a key feature of the PU.1 effect:
namely, that PU.1 actions are Notch-sensitive. Even artificially
high-level PU.1 could only redirect the differentiation of the cells
to myeloid or dendritic fates if Notch signaling were reduced
(49, 50, 58). In primary fetal-derived pro-T cells and in a DN3-
like cell line, the particular genes affected by a given, fixed
level of PU.1 in the cells depended strongly on the strength
of Notch signaling being induced in the cells at the time (58).
Notch ligands are the most important of all the environmental
signals that the thymus stroma provides to developing T cells,
apparently across all vertebrates (59–61), and Notch activated
target genes like Hes1 are expressed throughout the pro-T
cell phases (ETP to DN3), until T-cell receptor (TCR) gene
rearrangement (62–64) [reviewed in (65)]. Thus, throughout
the stages when PU.1 is expressed, the Notch signaling driven
in the normal thymus environment could guarantee that PU.1
expression would confer only a potential for differentiation to
alternative fates, which the cells would not actually follow unless
the thymic environment were disrupted. The silencing of Spi1
expression and permanent loss of PU.1 protein from the cells
at a later stage of differentiation would then make their loss of
myeloid potential unconditional.
The question raised by such results, however, was why PU.1
should continue to be expressed at all by cells once they entered
the thymus. Population dynamic models imply that the stages
when PU.1 is expressed occupy a minimum of 7–10 intrathymic
cell divisions of pro-T cells (39, 66, 67). If PU.1 was evolutionarily
selected to be expressed over such an extended period, it might
be playing an important role in pro-T cells, and this could be
despite or because of the Notch signaling conditions that were
preventing it from diverting the cells to a non-T fate. The earliest
stages of T cell development are not well understood, and it until
recently it was not obvious what function could be important to
the cells at this time a priori, other than proliferation. In the past
5 years, however, a detailed look at the molecular biology of PU.1
action on the genome in pro-T cells has revealed much about
the ways that PU.1 works, the complex cell biology of the early
precursor states, and previously under-appreciated principles of
transcription factor systems operating in development.
EFFECTS OF PU.1 LOSS ON T-CELL
DEVELOPMENT: THE CELLULAR VIEW
A Vital Role for PU.1 in Prethymic T-Cell
Progenitors
Disruption of PU.1 has long been known to eliminate or greatly
inhibit T-cell development, based on the dramatic phenotypes
from the first lines of PU.1-knockout (Spi1 knockout) mice with
unconditional, germline mutations (68–71). The question has
been how to interpret this severe effect, i.e., whether it is due to
loss of a function within the T-cell program itself, or whether it
simply reflects a loss of input cells to the pathway. One problem
was originally the lethality of the hematopoietic phenotype (death
either in late fetal development or immediately after birth), but
even when conditional knockouts were developed (2, 72), this
remained problematic. All the hematopoietic progenitors that
generate either B or T cells appear to originate from PU.1-
expressing, PU.1-dependent prethymic cells (2, 27); PU.1 is
directly required to maintain the expression of the cytokine
receptor Flt3 that is indispensable for progenitors with B
and T cell potentials (73). Thus, in postnatal mice, although
T cell development is much more severely affected by PU.1
deletion than neutrophil development (2), the effect could still be
prethymic. In stark contrast, if Spi1 is conditionally deleted in T-
lineage cells only after the cells have passed the DN2 stage, there
are very modest effects on T cells as a whole, apparently limited
to selective reduction of IL-9-producing T-cells (74), and some
loss of restraint on γδ T cells and T follicular helper cell activity
(75, 76). Is PU.1 actually needed within the T-cell pathway for
T-cell development at all, or is it simply needed to guarantee a
supply of prethymic progenitors?
Addressing this question in vivo was handicapped by
difficulties in the methods of inducing stage-specific Spi1
deletion. The question about a transient role for PU.1, but one
which might have strong effects on viability, makes it important
to have high penetrance and high synchrony of deletion as
well as fine developmental stage control, both of the deletion
and through the analysis afterwards. The widely-used T-cell
specific Cre expression constructs that might be appropriate for
thymocyte analysis, pLck-Cre and CD4-Cre, actually begin to be
expressed too late: pLck-Cre turns on just as PU.1 is turning off,
and CD4-Cre is expressed even later, after the rearrangement of
the first TCR genes. Constructs like Il7r-Cre or Rag1-Cre, which
may have prethymic expession but are also expressed much more
strongly during later pro-T cell stages, could make output cell
phenotypes difficult to interpret because of uncertainty about
when the deletion actually has become complete. Fortunately,
pro-T-cell differentiation cultures on OP9-DL1 or OP9-DL4
stroma that constitively present Notch ligands (77, 78) are ideal
for examining the stages relevant to PU.1 function, and a variety
of efficient retroviral vectors can transduce the cells at these stages
with high efficiency to introduce gain or loss of function agents.
These systems have proven to be valuable tools not only for
verifying the coarse-grained roles of PU.1 in pro-T cells, but also
for investigation of their molecular mechanisms.
PU.1 Promotes Proliferation While Slowing
Differentiation of Pro-T Cells
PU.1 is indeed important within the T-cell program as well as
before thymic entry, as shown by using in vitro differentiation
to provide conditions where PU.1 could be removed acutely
in a synchronized cohort of precursors and the fates of the
cells could be monitored immediately afterwards. In these
studies, floxed Spi1 was disrupted in the input cells few
days after T-lineage development had begun, using a Cre-
encoding retroviral vector (79). The deletion of PU.1 reduced
viable cell yield, but a co-transduced Bcl-xL transgene was
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added with Cre to prevent specific effects on development and
proliferation from being masked by cell death. Similar results
were obtained independently using Cas9 plus Spi1-specific guide
RNA to delete PU.1, and supporting cell viability with a Bcl2
transgene (80). In both experimental setups, PU.1 disruption
reduced T-cell precursor proliferation substantially as compared
to controls. PU.1-deficient cells underwent fewer cycles per
unit time than controls both in ETP stage and in DN2a/2b
stages (79), suggesting that even once the cells have begun to
express definitive T-lineage markers, they need PU.1 to sustain
optimal proliferation. However, of the cells that were generated
from PU.1-disrupted precursors, a substantially larger fraction
progressed to DN3 stage than in control cells, over the same
length of absolute developmental time, suggesting that they were
liberated from a differentiation constraint (79, 80).
Thus, endogenous PU.1 does have a functional role within
early T-cell development. It slows developmental progression of
pro-T cells even as it supports their early proliferation.While this
may seem paradoxical, it could fit well with a role to build the size
of the pre-selection pool of T-cell precursors before they progress
to commitment and then TCR gene rearrangement, so as to
maximize TCR gene rearrangement diversity in the population
as a whole before selection occurs (66, 81). The effect of PU.1 on
proliferation is conditional and dose-dependent, however. While
added PU.1 can enhance pro-T cell proliferation in response to
cytokine cocktails containing high levels of Stem Cell Factor (Kit
ligand) and Flt3 ligand or myeloid growth factors (38, 50), it
strongly inhibits the proliferation of pro-T cells under conditions
that do not reward the cells for lineage switching (49). Such
dose dependent effects are common for transcription factors as
for signaling molecules, in part because high concentrations of
these factors bind to inappropriate genomic sites, leading to off-
target effects. The target genes stimulated by PU.1 include both
pro-proliferative and G1-prolonging cell cycle effectors, whereas
some important proliferative genes are repressed when PU.1
levels are high (82, 83). Thus, both too much and too little PU.1
can have negative impacts on proliferation of the cells within a
similar developmental time window.
The in vitro assays used to define these roles (discussed in
more depth in the next section) are powerful because of the easy
accessibility of the developing cells during differentiation and
because of the ability to follow differentiation of a synchronized
cohort of cells in absolute time. As described below, however, the
genes most sensitively regulated by PU.1 in developing T cells
suggest that this factor may be important to endow cells with
additional functions as well, functions that may only contribute
to their development specifically in the thymus in vivo.
DEFINING THE PU.1 REGULOME IN EARLY
T-CELL PRECURSORS
Cell Line and Primary-Cell Assay Systems
for PU.1 Manipulation
To explain the roles of PU.1 in T cell development, it is crucial to
take into account its developmental expression pattern. Its high
expression in early-stage pro-T cells followed by downregulation
FIGURE 2 | Framework for experimental perturbation studies to define
functions of PU.1 in early thymic development. Stages of cells are as in
Figure 1 (DN3: primarily DN3a). Exogenous PU.1 is added by retroviral
transduction. Note the dependence of the PU.1 functions tested upon the
timing of the experimental perturbation. Endogenous PU.1 can be deleted by
Cas9 plus single-chain guide RNAs (sgRNA) against Spi1, or by introducing
Cre into cells with floxed Spi1 alleles. PU.1 can also be neutralized by adding a
dominant negative construct. The DN2a-DN2b interval is accessible to
experimental perturbation. The approximate developmental stage represented
by the Scid.adh.2C2 cell line (see text) is also shown [Schematic adapted from
Ungerbäck et al. (85)].
during commitment means that its direct effects have to
be correlated with developmental stage. Thus, any inferred
role must be validated by developmental stage-dependence of
putative target gene expression patterns or of chromatin features
that characterize its binding sites. To look more closely at how
PU.1 actually regulates specific target genes, acute gain and loss
of function experiments are needed. Despite some overlap in
occupancy, PU.1 binding sites and PU.1 binding partners are
not the same in early T-cell precursors as in myeloid cells or
B lineage cells (13, 80, 84, 85), a similar situation to its early
role in erythroblasts (86). Therefore, these assay systems need to
be based on pro-T cells (Figure 2). Exogenous PU.1 can easily
be introduced into developing murine T-cell precursors using
retroviral vectors for gain of function studies (46–50, 58, 80, 85).
For loss of function, retrovirally transduced Cre can induce acute
deletion in pro-T cells from Spi1fl/fl strain mice (79); and in
Cas9-transgenic pro-T cells, retrovirally transduced guide RNAs
(sgSpi1) can target rapid, biallelic disruption of the Spi1 locus
(80, 85). Figure 2 introduces the way the primary-cell and cell-
line models can be manipulated to relate experimental gain-of-
function and loss-of-function PU.1 experiments to the normal
dynamics of endogenous PU.1 expression.
A very useful model cell line, Scid.adh.2C2, has made it
possible to study PU.1 gain of function in a pro-T cell-like
context (47). These cells are convenient because they are readily
transfectable, retrovirally transducible, and fast-growing, so that
cell numbers are not limiting and the developmental baseline
is mostly static, all major advantages for genomic comparisons.
These cells were a subclone derived from the Scid.adh cell
line (87) and are similar to developmentally arrested versions
of committed DN3 pro-T cells, lacking any expression of
endogenous PU.1 (47). Despite being an immortal cell line,
these cells are developmentally transformed by introduction
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of exogenous PU.1. They respond in an all-or-none way to
forced expression of PU.1, coordinately upregulating myeloid-
or dendritic-cell associated genes and downregulating T-cell
genes in a discrete fraction of the cells that increases with
increasing levels of PU.1 (47, 58), resembling responses of
primary fetal or postnatal pro-T cells (46–50, 58, 80, 85). The
switch-like nature of this response was an important early clue
to the regulatory circuit interaction between PU.1 and the Notch
signaling pathway (49, 58).
Useful and informative as it is, this system is limited as a way
to study the roles of endogenous PU.1 in vivo. The sites occupied
by exogenous PU.1 in Scid.adh.2C2 cells overlap highly with
the sites occupied by endogenous PU.1 in normal pro-T cells,
but the match is by no means complete (85). Even with PU.1
transduction, Scid.adh.2C2 cells do not restore the full chromatin
accessibility landscape of ETP and DN2a stage pro-T cells, and
despite detectable upregulation of a few other early pro-T cell
genes (e.g., Bcl11a and Lyl1), the transduced cells as a whole
reactivate little of the program that forms the normal context for
endogenous PU.1 activity in pro-T cells (58, 79, 85). Therefore,
PU.1 has to bemanipulated acutely in dynamically differentiating
primary cells.
To focus the introduction of PU.1 into cells at a particular
developmental stage, it has proven to be very useful to exploit
the powerful in vitro T-cell development systems based on co-
culture of primary-cell precursors on OP9-DLL1 (aka OP9-
DL1) or OP9-DLL4 (OP9-DL4) stroma with IL-7 and Flt3L
(78, 88), or similar systems using other stromal cell lines to
express the Notch ligands DLL1 or DLL4. Either fetal-liver-
derived precursors or adult bone marrow-derived precursors
develop efficiently along the T cell lineage in these systems with
strong proliferation through the stages around commitment,
allowing the stages to be separated both by flow cytometric
phenotypes and by absolute times of differentiation. In these
open systems, the cells can be harvested easily at any time point,
transduced with vectors, treated with drugs, and/or sorted, and
then shifted to the same or a different culture condition for
further development. These systems have been indispensable for
deeper analysis of the molecular mechanisms that PU.1 uses to
regulate development of pro-T cells. However, two issues have
to be taken into account in these analyses, both arising from
features that amplify the developmental impact of PU.1. These
are reviewed in the next sections.
Developmental Challenges: Implications of
a Gene Regulatory Network Switch
The ideal conceptual framework of PU.1 gain of function
experiments is to start with pro-T cells that have recently
turned off their endogenous PU.1 expression and to assess
how their developmental state is affected by re-introducing
PU.1 expression, comparing the impact of exogenous PU.1 with
the pre-commitment gene expression pattern. Ideally in this
scenario, restoring PU.1 after commitment should promote some
aspect(s) of retrograde differentiation. Both Scid.adh.2C2 and
normal DN2b/DN3 pro-T cells make strong responses to forced
expression of PU.1, as noted above, and often the response
includes downregulation of multiple later T-cell differentiation
genes. Does this shed light on PU.1’s natural role in earlier
T-cell development, or is it simply an inhibitory artifact of
overexpression? Clues that the gain-of-function phenotype is
linked with a genuine role of PU.1 in earlier T-cell development
come from PU.1’s (re-)activation of a group of genes that are
specifically associated with the early progenitor state, including
Bcl11a, Mef2c, Hhex, and Lmo2 (58, 79, 85). Some of these are
also upregulated in human T-acute lymphoblastic leukemias with
highly expressed PU.1 fusions, as well (38).
However, the power of the response raises caveats about
interpretation because of an important systemic feature of
the PU.1 role in development. In primary pro-T cells and
Scid.adh.2C2 cells, highly overexpressed PU.1 appears to inhibit
Notch signaling, as measured by downregulation of Notch target
genes and even Notch1 itself. Whether cause or effect, this
collapses the balance between Notch signaling and PU.1 activity
that is fundamental to channel the natural role of PU.1 in early
pro-T cells (see above) (49, 58). The most pronounced effects
of PU.1 are thus a nonlinear response to PU.1 dosage mediated
through a gene network switch (Figure 3), and this gene network
switch underlies the stochastic, switch-like behavior of individual
pro-T or Scid.adh.2C2 cells when forced to express high-level
PU.1 (47, 58). Importantly, the combination of PU.1 with
Notch signaling desensitization pushes the cells out of the T-
cell program completely, rather than simply reversing their
progression through the T-cell program. Instead of re-acquiring
aspects of a progenitor-like state, the cells appear to trans-
differentiate to a dendritic-cell or macrophage developmental
program (48, 50, 58).
In newly-committed primary pro-T cells forced to express
PU.1, the cells crossing this developmental boundary are seen
to downregulate the Notch-dependent DN2/DN3 stage marker,
CD25 (Il2ra), and often upregulate the myeloid-associated
marker CD11b (Mac1; Itgam). The gene expression profiles
of cells losing CD25 and upregulating CD11b are radically
transformed from the state of newly-committed pro-T cells
within 2 days after transduction, with widespread repression
of T-lineage-affiliated transcription factor genes and Notch
target genes as well as upregulation of multiple Cebp and Irf
family transcription factor genes (Figure 4) (85). This response
is quite different in gene expression pattern from retrograde
differentiation to an ETP- or DN2a-like phenotype. In contrast,
cells remaining within the T-cell pathway, continuing to express
CD25 and remaining negative for CD11b, show relatively modest
and selective changes in gene expression driven by upregulated
PU.1, with minimal loss of T-cell regulatory gene expression
(79, 85). Details of these transcriptome effects are discussed in a
later section, but the point here is that they include qualitative as
well as quantitative differences in the gene expression responses.
The differences in average Spi1 overexpression levels between
cells making these two responses are only on the order of ∼2–
3 fold (pink, dark red bars in Figure 4), so it is very likely that the
additional changes in other regulatory genes contribute strongly
to this global shift. Thus, the effect of PU.1 expression per se
may be part of the normal T-cell program, but under high-level
expression conditions it combines with additional, conditionally
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FIGURE 3 | PU.1 and Notch collectively determine T vs. myeloid lineage fates.
(A) Notch signaling within the thymus normally constrains PU.1 effects to
support early pro-T cell development while blocking alternative fates that PU.1
would otherwise promote. Notch signaling itself does not repress PU.1
expression; however, other transcription factors induced by Notch signaling
eventually silence expression of Spi1 during the DN2b stage. (B) Separation of
the effects of PU.1 within the T-cell pathway from effects of PU.1 to promote
lineage deviation, in PU.1 gain of function experiments. A fraction of cells
expressing high levels of PU.1 shift to a myeloid-like state that can be
phenotypically distinguished from cells remaining within the T-cell state. This
distinction is necessary to relate gain-of-function effects of PU.1 in pro-T cells
to effects of loss of endogenous PU.1 in perturbation experiments. Lineage
deviation is associated with a broad loss of Notch signal response in the cells,
suggesting that the constraint mechanism shown in A has been overwhelmed
in these cells. Biochemical mechanisms of these effects remain to be fully
defined. Schematic in A, adapted from (58); in B, adapted from (85).
induced mechanisms to produce a much broader spectrum of
developmental effects that may not only be direct responses to
PU.1 itself.
Kinetic Challenges: Protein Half-Lives vs.
Developmental Progression
Loss of function approaches are indispensable to confirm the
roles of endogenous PU.1, especially in view of the potential for
indirect effects in gain of function experiments, just described.
Here, the challenge has been to find a way to remove or neutralize
the endogenous factor quickly enough to see effects robustly,
while keeping the controls and the experimental samples at
comparable developmental stages. One problem is that the long
half-life of PU.1 protein (82) can mask some loss effects at time
points <2 days after deletion, while development of the pro-T
cells can proceed to new stages if time windows are extended
further. There are thus several problems with generating high-
quality samples for analysis of transcriptome changes caused
by PU.1 loss of function. Cre-dependent deletion of a loxP-
flanked Spi1 allele (Spi1fl.fl) is asynchronous, and in an early T-
cell population with mixed degrees of Spi1 deletion, cells with
inadequate PU.1 levels appear to be at a selective disadvantage,
even in vitro. Ironically, because PU.1 protein can persist longer
than a cell cycle (82), the very slowdown of cell division caused
by deletion of Spi1 (see above) can also interfere with the dilution
needed to complete the clearance of the PU.1 protein. As a
result of the enrichment of cells with undeleted alleles, and this
persistence of pre-existing PU.1 protein even from the cells that
have successfully deleted its coding gene, the effects on target
gene regulation appear very weak at timepoints up to 2 days
after PU.1 deletion, despite the fact that the reduced cell yields
from the knockout cells show that PU.1 is biologically important
(79). If timepoints are taken too long after deletion, the controls
progress to the point when endogenous PU.1 is downregulated,
so that any truly PU.1-dependent targets are expressed weakly
in the controls, and comparisons with the knockout samples
again lose statistical power. A very intriguing new prospect
for fast antagonism of PU.1 activity is the discovery of small-
molecule inhibitors, some of which are highly potent and specific
at blocking PU.1 action in leukemia cells; however, these have not
yet been tested for effects on normal T-cell development (89).
A relatively fast way to neutralize PU.1 protein activity directly
has been to transduce the cells with a “dominant negative”
obligate repressor derivative of PU.1, a fusion protein of the PU.1
DNA binding domain with the repression domain of Drosophila
melanogaster Engrailed (PU.1-ENG), to compete for binding
against endogenous PU.1 (79) (comparison with wildtype PU.1
shown in Figure 5). The obligate repressor should affect PU.1
positive regulation targets in the opposite direction fromwildtype
PU.1, and in theory should affect PU.1 negative regulation targets
in the same direction, an “algebraic sign” distinction that could
be used in principle to dissect indirect effects as well (79). This
construct has been useful to reveal quick impacts on expression of
positively regulated PU.1 target genes, many of which have been
confirmed later by other approaches (85). For example, whereas
PU.1 itself can upregulate progenitor-associated genes Bcl11a,
Lmo2, Mef2c, and Hhex above their normal levels in DN2a and
DN2b primary cells, PU.1-ENG can downregulate them (79).
However, PU.1-ENG also has some spurious effects and cannot
access closed chromatin sites as well as full-length PU.1 (79, 85).
Cas9-dependent acute deletion of the Spi1 locus can be fast
and highly efficient due to the availability of Cas9-transgenicmice
(92) and vectors that can be used for high-level, synchronous
expression of guide RNAs. However, deletion and clearance of
PU.1 protein in this system still require analysis >2 days after
introduction of the guide RNAs (80, 85), and the continuing
developmental progression of both knockout samples and
controls needs to be taken into account in interpreting the
results. The strongest evidence for specific physiological PU.1
effects therefore comes from the consensus results from two or
more of these perturbation systems. The highest confidence list
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FIGURE 4 | Profound changes in regulatory gene expression distinguish PU.1-induced lineage deviation from PU.1 effects within the T-cell pathway. Charts show
changes in expression of the indicated genes (log2 Fold Change relative to controls) induced by introduction of PU.1 into post-commitment pro-T cells (DN2b-DN3).
Panels compare effects on T-lineage regulatory genes (top) and non-T regulatory and signaling genes (bottom) between cells remaining within the T-lineage pathway
(light blue bars) and cells undergoing lineage deviation (dark blue bars). Light, dark red bars show corresponding measured levels of exogenous PU.1 in these samples,
as log2 fold changes over controls, which have downregulated most of their endogenous PU.1 expression at this stage. Results are from Ungerbäck et al. (85).
of potential PU.1 target genes in pro-T cells could be defined
as genes that responded reciprocally to gain and loss of PU.1
function within the same DN2a-DN2b developmental interval,
and these genes are listed in Table 1. While this list under-
represents some PU.1 targets that are only expressed in ETP
stage, rigorous definition of the genes that are directly regulated
by PU.1 in pro-T cells has made it possible to investigate the
range of mechanisms used by the PU.1 protein to exert these
transcriptional effects.
PU.1 ACTION ON THE GENOME VIA
DIRECT BINDING
PU.1 Protein Is Stable and Active Across
the Genome in Early T Cells
Most of the initial hypotheses about PU.1’s role in T-cell
precursors were based on Spi1 RNA expression patterns and
on forced expression of exogenous PU.1 to supra-physiological
levels (46, 48–50). With the advent of ChIP-seq data, though,
it was confirmed that endogenous, naturally expressed PU.1
is indeed a prominent actor across the genome in T-cell
precursors before commitment. PU.1 was found binding to
>30,000 genomic sites in these cells at the earliest stages (84),
and intracellular protein staining confirmed that some PU.1
expression is still detectable at later stages, in the same individual
cells that go through T-cell commitment (marked by activation
of the Bcl11b gene) (33, 93). In addition, although the RNA
transcript levels are modest in absolute terms, the impact of PU.1
on the cells can be magnified by the high stability of PU.1 protein
(82). Although PU.1 occupancy of genomic sites declines as
development proceeds, PU.1 occupancy is still detectable through
T-lineage commitment at∼5,000 sites before disappearing (84).
PU.1 Binding Site Characteristics
The sites where PU.1 binds are enriched for open chromatin
as defined by DNase accessibility or ATAC-seq [assay of
transposase-accessible chromatin (94)], and circumstantial
evidence suggests that PU.1 is a major factor at those sites that
change activity during commitment. PU.1 recognition motifs
are the most highly enriched of all defined motifs at sites that
start out highly accessible in early pro-T cell stages, when
PU.1 is present, and lose accessibility during commitment, i.e.,
as PU.1 levels decline (44, 85, 95). PU.1 itself is functionally
important for the open status of these chromatin sites in the
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FIGURE 5 | PU.1 structure and derivatives of PU.1 used for functional
analysis. Domain boundaries within the amino acid sequence of murine PU.1
are depicted with their associated functions indicated at the top (4, 18, 90, 91).
Epitope-tagged wildtype PU.1 (PU1WTHA) and two epitope-tagged, modified
constructs are shown (PU1ENGHA, PU1ETSHA); these are used to interrupt
endogenous PU.1 activity (79, 82). PU1ENGHA and PU1ETSHA have a full
DNA binding domain and efficiently enter open chromatin, but are deficient in
entering closed chromatin (85). DE: Acidic residue-rich transactivation domain.
Q: Glutamine-rich transactivation domain. PEST: Proline, Glutamate, Serine
and Threonine-rich domain, site of IRF4 and IRF8 interaction (interx). Note that
in PU.1 this “PEST” domain does not make the protein unstable. ETS:
E-twenty-six proto-oncogene homology domain, the DNA binding domain of
PU.1. This is also the region that interacts with basic leucine zipper (bZIP)
factors such as Jun and C/EBP factors, and GATA family factors.
early stages, for many of these sites in fact do not remain as
open if the PU.1 is removed acutely from primary pro-T cells
by Cas9-mediated deletion (85). This is consistent with PU.1’s
activity as a site-specific chromatin opening factor in B cells
(96, 97), with the ability of PU.1 to eject nucleosomes from sites
where it binds in macrophage lines (12), and with its ability to
cause rapid increases in ATAC accessibility at the sites it occupies
when introduced into Scid.adh.2C2 cells (85). While PU.1 binds
at both promoters and non-promoter sites, the evidence from
both gain and loss of function studies shows that PU.1 is most
associated with chromatin accessibility when it is binding at
non-promoter sequences, within introns of genes or in intergenic
regions. As described in detail below, such sites, where PU.1
itself is important to maintain chromatin accessibility, are the
ones most often linked to genes that are positively regulated in
their expression by PU.1 (85). Thus, PU.1 action to keep sites
open in chromatin may be an important way that it promotes
transcriptional activation in pro-T cells.
Because PU.1 mediates different effects in the rather
different regulatory contexts of B, dendritic, myeloid, erythroid
progenitors and pro-T cells, an important question is how much
of PU.1’s binding choice hierarchy is dependent on the prior
epigenetic history of cells. PU.1 cannot enter all genomic sites.
Notably, PU.1 appears to be excluded from genomic regions
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This table lists high-confidence PU.1-regulated genes which show reciprocal responses in
the loss of function and gain of function perturbations of PU.1. The lists give the three-way
intersection of genes affected in loss of function, and (reciprocally) in gain of function within
cells remaining CD25+, and in gain of function within cells becoming CD25− CD44+.
Consensus PU.1-repressed target genes: genes with expression that goes down in PU.1-
transduced DN2b with or without lineage diversion (CD25+ or CD44+ cells), and also
increases in normal DN2a cells after deletion of endogenous PU1. Consensus PU.1-
activated target genes: genes with expression that increases in PU.1-transduced DN2b
with or without lineage diversion, and also goes down in normal DN2a cells after deletion
of endogenous PU.1. Data compiled from Ungerbäck et al. (85).
that are packaged in Polycomb Repressive Complex 2-modified
chromatin, as marked by trimethylation of Histone H3 Lysine
27 (H3K27me3) (84). However, approximately half of the PU.1
occupancy sites in early pro-T cells appear to be relatively
“inaccessible” in chromatin by the criterion of ATAC-seq at the
stages when PU.1 is seen to be binding there, showing that PU.1
binding can occur without opening the chromatin. These sites
in closed chromatin have particularly high-quality matches to
the consensus PU.1 binding position weight matrix (85), which
several lines of evidence show to be a good indicator of PU.1
binding affinity (11, 85). This suggests that closed chromatin
may be less permissive to PU.1 binding than open chromatin, so
that only high-affinity site recognition allows binding in closed
regions. However, this stringent specificity criterion also shows
that these are not “off-target” sites: the tradeoff between site
accessibility and the affinity of binding needed for occupancy
indicates that PU.1 itself is identifying these sites in closed
chromatin to establish its occupancy. By the ability to enter closed
chromatin at its own high-affinity sites, and by its functional role
in controlling chromatin accessibility at other sites, PU.1 meets
the criteria for “pioneer” factor activity in early pro-T cells (98),
and the scope of its binding suggests a broad role in genomic
architecture of these cells.
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Still to be determined are the rules determining when PU.1
binding to closed chromatin results in opening of the closed
site. A priori, one could imagine that PU.1 establishes occupancy
using its DNA-binding domain and then uses its protein-
interaction domains to recruit chromatin modifying complexes
(Figure 5, diagram of structures). Many of the known protein-
protein interactions between PU.1 and other transcription factors
on the DNA are also mediated through parts of the DNA
binding domain, consistent with a compartmentalized role of this
domain of the protein for binding site choice [reviewed in (18)].
However, PU.1 also contains non-DNA binding domains, acidic
and glutamine-rich “transactivation” domains and an IRF4/8
binding domain, that are also clearly implicated in PU.1 function,
as selective deletions of these domains greatly reduce PU.1
developmental impacts (24, 47, 99). Recent evidence has pointed
to another role of the non-DNA binding domains of PU.1, a
function needed for PU.1 to enter closed chromatin. Genome-
wide, exogenously introduced full-length PU.1 and the isolated
PU.1 binding domain establish quantitatively similar patterns
of occupancy at open sites and especially at open promoters all
across the genome. However, they show a marked difference in
binding between open and closed chromatin, especially at non-
promoter sites. Full-length PU.1 binds closed sites nearly as well
as open sites, whereas the isolated PU.1 DNA binding domain
binds open sites as well as full-length but selectively fails to bind
at closed sites (85) (Figure 6). This suggests that an additional
process beyond simple DNA sequence recognition is required to
establish PU.1 occupancy in closed chromatin, even without an
overt change in chromatin accessibility as measured by ATAC-
seq. A similar mode of action has already been described for a
separate, non-DNA binding domain to enable EBF1 entry into
closed chromatin (100). It will be interesting to see if this is a
general feature of pioneer transcription factors.
PU.1 ACTION VIA COFACTOR
RECRUITMENT
Direct Gene Regulation by PU.1: Activation
by Distal Enhancer Engagement and
Opening
The major problem with connecting PU.1 binding to PU.1
regulatory function is that PU.1 binds to too many genomic
sites in ETP and DN2a pro-T cells (84). It shows high fidelity
in terms of sequence recognition, but its binding is not confined
to functionally responsive target genes. It is found at a large
fraction of open, accessible chromatin elements during the
stages when it is expressed, and often bound at promoters as
well as distal elements. However, only a minority of the genes
linked to its binding sites change expression at all across the
developmental interval when PU.1 goes from full expression to
silence (84). Much of PU.1 binding in pro-T cells thus appears
to be either functionally redundant or opportunistic. Identifying
PU.1’s functional mechanisms of target gene regulation has
required a way to link an experimentally inducible change in
PU.1 binding at a given site with the rapid, measurable change
in expression of the target gene linked to that site. This is
considerably easier to do in a gain of function format than in loss
of function, as an epitope-tagged exogenous PU.1 construct can
be introduced with fast kinetics and its newly established binding
tested for association with local gene expression responses (85).
Note that the gain-of-function experimental design makes it
necessary to use another criterion to screen out genes that are
only indirectly affected, as described above. For this reason, in
our recent study (85) only cells that remained CD25+ CD11b−
(see above) were used for ChIP-seq analysis of exogenous
PU.1 binding.
The results showed that PU.1 exerts its main functional
regulatory impacts in pro-T cells via non-promoter sites, and
especially via sites that are normally developmentally changing
in chromatin accessibility (85) (Figure 6). In the aggregate, most
of the responses of genes linked directly to PU.1 binding sites
were positive; direct repression targets were much rarer. Genes
responding to the addition of exogenous PU.1 usually had
the exogenous PU.1 binding to distal (intronic or neighboring
intergenic) sites, whereas genes that had PU.1 binding only to
their promoter regions usually did not change expression at
all. In the “blank slate” background of the Scid.adh.2C2 cell
line, exogenous PU.1 binding opened chromatin at its non-
promoter sites within 2 h, increasing the “activating” H3K27Ac
marks at these sites a few hours later, and the linked genes were
predominantly upregulated within 8–24 h. The genomic sites that
were most highly associated with these responses in primary pro-
T cells were developmentally dynamic in chromatin accessibility:
normally open in early stages of T-cell development (endogenous
PU.1-expressing) but closed once the cells went through
commitment (endogenous PU.1-low or negative). Thus, the sites
in pro-T cells with the strongest sensitivity to exogenous PU.1
for transcriptional impact were also sites where endogenous PU.1
might be important for maintaining chromatin accessibility.
The Problem of Pro-T Cell Gene
Repression by PU.1
The impact of PU.1 on pro-T cell gene expression overall is at
odds with the biochemical and genomic evidence for its mode
of action in one respect: PU.1 introduced into primary pro-
T cells or Scid.adh.2C2 cells causes downregulation of many
T-cell genes, especially those associated with Notch signaling
and TCR gene rearrangement after commitment. This response
is fast, reducing existing transcript pools for many repressed
genes even before most positively regulated PU.1 target genes
are seen to be turned on (80). However, the local impact of PU.1
binding is strongly biased toward activation of genes linked to the
binding sites. While much of the data showing T-lineage affiliated
gene downregulation comes from forced PU.1 re-expression or
overexpression experiments, and might therefore be a high-dose
artifact, it is important to note that the developmental speed-
up observed in primary pro-T cells when PU.1 is knocked out
also points to a normal PU.1 role as a brake on developmental
progression (79). Thus, to account for PU.1’s overall role, some
explanation for the repressive outcomes is essential.
There is a long history of research on PU.1 as a repressor
of genes associated with non-myeloid pathways, especially in
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FIGURE 6 | Summary of PU.1 binding features in pro-T cells. (1) PU.1 binding is preferentially retained at high-affinity sites as pro-T cells progressively reduce their
PU.1 levels. This feature indicates that PU.1 primarily uses mass action (concentration × affinity) to determine its genomic site choices in these cells. (2) PU.1 works as
a positive regulator in pro-T cells primarily by binding and controlling accessibility of sites distal to the transcriptional start sites, not at promoters. (3) The binding
profiles of full-length PU.1 (PU1WT) show a tradeoff between binding site affinity and binding site accessibility in chromatin; however, constructs with the PU.1 DNA
binding domain but lacking the transactivation domains (PU1 DBD) are poor at engaging sites in closed chromatin no matter how high their potential affinities.
the context of PU.1—GATA-1 antagonism in hematopoiesis
[reviewed in (4, 7, 25)]. At high levels, PU.1 has been found
to block DNA binding by GATA-1 (23), while at lower levels
it is reported to antagonize GATA-1-mediated transactivation
by forming complexes with it that recruit Rb through the PU.1
acidic transactivation domain (101). It is also reported to act as a
repressor by direct recruitment of Dnmt3b (102). Inmost of these
cases, PU.1 is observed to bind directly to the regulatory DNA
of its repression targets (86, 103). However, in the pro-T cells,
the genes that are repressed when exogenous PU.1 is introduced
are not necessarily linked to the sites that the exogenous PU.1
actually binds. In fact, results with the PU.1-ENG obligate
repressor construct implied that some kind of indirect effect must
be involved: while the obligate repressor downregulated genes
that are positive regulatory targets of wildtype PU.1, it actually
upregulatedmany genes that wildtype PU.1 represses, completely
inconsistent with a direct repression mechanism (79).
To date, three mechanisms appear to be involved. First, as
noted above, high-dose PU.1 can inhibit expression of multiple
Notch target genes and Notch1 itself (58, 85). It is possible that
the fast downregulation of Notch response genes, includingHes1,
Nrarp, Dtx1, Lef1, and Il2ra, by overexpressed PU.1 is due to
the loss of positive Notch signaling input rather than to a gene-
specific mechanism. This Notch-inhibitory mechanism is not
operating in cells that remain within the T-cell pathway, but it
becomes prominent in cells that PU.1 causes to transdifferentiate,
and would be expected to affect all T-cell genes that use Notch
signaling as an obligate positive input, whether or not PU.1
binds them directly. A related scenario in which PU.1 could
interfere with a T-lineage specific positive regulatory input might
be through repression of GATA-3 by PU.1, by analogy with the
cross-inhibition of PU.1 and GATA-1. However, in pro T cells,
both PU.1 and GATA-3 are active together and both functionally
important throughout the ETP to DN2a stages (79, 104), and
there is more evidence for GATA-3 repression of PU.1 than for
PU.1 repression of GATA-3 (58, 79, 104, 105). However, GATA-3
function also may become a casualty of PU.1 action when Notch
signaling is inhibited (58).
Second, in pro-T cells forced to express PU.1, those that
make the lineage jump (i.e. lose CD25, gain CD11b) not
only silence Notch1 but also activate myeloid regulatory genes
(85). They also begin to express multiple transcription factors
of the Egr and IRF families, and in the case of primary
cells, they also upregulate C/EBP family factors. These factors
probably contribute independently to the repression of pro-
T cell genes. Egr2, for example, can collaborate with PU.1 in
positive regulation when co-bound with it (106), but has also
been implicated as a PU.1-stimulated repressor of the mir17∼92
complex (107). Although not required for Notch1 repression
in Scid.adh.2C2 cells (58), when activated in primary cells,
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C/EBPα itself can also repress Notch1 (50). PU.1 does not
strongly upregulate transcription factors annotated as repressors,
however, in cells remaining within the T-cell program (see
below). Therefore, this indirect repressive activity, too, would
only be deployed under conditions of lineage shift.
The third mechanism that could play a role in repression
within the T-cell program comes from PU.1’s own ability to
recruit other transcription factors to collaborate with it at
PU.1 binding sites. This is a hallmark of pioneering activity
in developmental gene regulation (98, 108), but in this case it
exposes a particularly intricate post-transcriptional relationship
between PU.1 and the factors required for progression of the
T-cell program.
System Consequences of Cofactor
Recruitment: Repression by Theft
PU.1 is a powerful organizer of the occupancy patterns of
other transcription factors genome-wide. PU.1 binding shifts the
disposition of other factors in the cell across the genome, even
when their own expression levels and total numbers of binding
sites remain essentially unchanged (80). The positive regulatory
significance of these kinds of shifts is well established; many
factors recruit others to collaborate with them in functional
complexes at active enhancers [e.g., reviews by (17, 109–111)],
and PU.1 is known to establish preferential binding sites for
multiple other transcription factors in myeloid cells. However, in
this case the positive impact is coupled with a negative regulatory
consequence, via action at a distance (Figure 7). For PU.1 in pro-
T cells, IRF and C/EBP family partners are mostly not available,
but a key positive regulatory partner is Runx1 (previously known
as AML1 or CBFα2), which has long been known to interact
with PU.1 (and C/EBPα) to form a functional complex at its
myeloid positive regulatory target sites (9, 112, 113). In pro-
T cells, PU.1 binding sites in open chromatin genome-wide
are highly enriched for Runx motifs, raising the possibility that
Runx factors assist in the chromatin opening process (85), and
proteomic analysis provides support for a strong representation
of Runx1 in PU.1-containing complexes formed in the pro-T cell
like Scid.adh.2C2 cell line (80). However, Runx1 also has sites at
a large fraction of all enhancers active in the cells without PU.1
expression (Figure 7).
When epitope-tagged PU.1 was introduced into Scid.adh.2C2
cells and the complexes were isolated for proteomic analysis,
much enrichment was seen for SWI/SNF complex components as
well as some other chromatin modifiers (80). The preponderance
of SWI/SNF complex interactions was consistent with the
evidence that PU.1 usually acts as an activator. Based on
the longstanding literature of PU.1–GATA factor antagonism
through protein interaction (20–23), GATA-3 was expected to be
present as well, and it was detectably enriched over background
in these complexes. However, by far the most highly enriched
sequence-specific transcription factor proteins interacting with
PU.1 in these cells were Rest and Runx1 (80). Runx1 was of
particular interest because of its sequence motif enrichment
at PU.1 sites. Although Runx1 can act as a global chromatin
accessibility organizer (114), PU.1 itself does not depend on
Runx1 for establishing permissive sites for its binding, even in
the “blank slate” context of the Scid.adh.2C2 cells (85). However,
PU.1 strongly affected the sites where Runx1 bound, resulting in
a dramatic shift in Runx1 binding site choices in tests of gain
of PU.1 function (80). Supporting the physiological relevance
of this mechanism, many of the same genomic sites where
Runx1 was shifted by PU.1 in Scid.adh.2C2 cells underwent
the reverse changes in Runx1 occupancy in normal primary
pro-T cells, as they progressed from PU.1-high to PU.1-low
developmental stages.
As expected, PU.1 recruits Runx1 to sites where Runx1 exerts
measurable functional collaboration with PU.1, mostly to help in
the positive regulation of PU.1 targets (80). However, the aspect
of this redistribution that is most notable is that Runx1 is depleted
in the process from alternative sites, and the sites that it abandons
are themselves highly functional sites. The analysis is somewhat
complicated by the fact that many developmentally important
genes are linked with multiple Runx1 and/or PU.1 binding sites,
only some of which gain or lose Runx1 occupancy. However,
focusing on those genes that have Runx1 binding sites but not
PU.1 binding sites, the genes that “lose” Runx1 binding when
PU.1 is expressed clearly include a large fraction that depend
quantitatively on Runx1 for their own expression. These genes
showweak downregulation when Runx1 is disrupted by Cas9 and
they show stronger downregulation when Runx1 is neutralized by
a Runx1 dominant negative construct (80). Thus, the competition
for Runx1 protein by PU.1 directly causes coupled positive and
negative regulation, to cause a switch-like alteration in genome-
wide cell state (Figure 7).
Three features of this mechanism are noteworthy (80). First,
PU.1 does not appear to bind, even transiently, at the sites from
which Runx1 is lost: Runx1 is competitively redistributed, but
is not displaced. Thus, the PU.1 effect differs from “squelching”
or other negative regulatory mechanisms where transcription
factors are expelled by chromatin closing (115, 116). Second,
one might expect that the Runx sites available for redistribution
could have been vulnerable to dissociation because they were
marginal quality binding sites in the first place; however, motif
analysis shows that many of the Runx occupancy sites that
are emptied when PU.1 is in the cell are high quality Runx
sites in the upper half of the position weight matrix score
distribution (80). Considered only as Runx sites, they are likely
to be much higher affinity than the ones to which Runx1 moves,
to occupy together with PU.1. Thus, the ternary (or higher-
order) complexes nucleated by PU.1 are more favored binding
sites for Runx1 when PU.1 is present than functionally relevant,
high-quality Runx sites elsewhere. Finally, it is clear that this
is a system-level mechanism. It is the limited pool of Runx1
operationally available for action across the genome that makes
the impact of PU.1 a “zero-sum” outcome. Thus, the regulated
level of Runx1 protein contributes to the switch-like impact made
by the developmental shift from high-level PU.1 to PU.1 shutoff.
However, given the high frequency of Runx factor utilization at
multiple lymphoid enhancer sites, this kind of mechanism can
propagate local PU.1 impacts to a much broader genomic scale.
The “theft” mechanism of repression by partner factor
redistribution is not unique to the PU.1-Runx1 pair. PU.1
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FIGURE 7 | Repression by PU.1 can be caused by redistribution of a limiting co-regulator (co-regulator theft). Schematic depicts the complementary changes in factor
binding patterns as well as in transcriptional activity of genes that are normally PU.1-dependent (right) or PU.1-inhibited (left), across the developmental stages when
PU.1 goes from high to low (top) and then in an experimental condition when PU.1 is re-introduced into committed cells that have already turned off endogenous
PU.1 (bottom). The figure shows that the redistribution of partner factors Runx1 (R) and Satb1 (S) by recruitment to PU.1 (P) binding sites occurs at the expense of
sites that these factors would otherwise occupy together with other T-cell factors (T). Broken-line arrows (lower left) indicate that redistribution probably involves the
dynamic equilibrium of binding of these factors between genomic sites that are differentially preferred in the presence and absence of PU.1. In at least some cases, the
“theft” of the cofactors also results in relative closing of the chromatin at sites from which these cofactors are removed. Schematic modified from Hosokawa et al. (80).
has an even stronger effect on binding site choice of Satb1,
another transcription factor that is expressed throughout early
T-cell development, and GATA-3 also shifts, when PU.1 is
added, to occupy sites together with PU.1 (80). Although Satb1
in DN2-DN3 stages appears to have weaker effects on gene
expression than Runx1, the PU.1-repressed genes that appear
to be responding to Satb1 loss are different from those that are
most dependent on Runx1, broadening the full impact of this
mechanism (80). A very similar phenomenon has been reported
earlier by Jenner and colleagues for the effect of T-bet on GATA-
3 in establishing the Th1 cell program (117, 118). Thus, “partner
factor theft” can be an integral part of the machinery for program
choice operated by lineage-determining transcription factors.
THE PU.1 REGULOME IN EARLY PRO-T
CELLS AND ITS PHYSIOLOGICAL ROLES
PU.1 Target Genes: Gene Network Roles
and Developmental Timing
While indirect regulation plays a large role in its developmental
impact, the target genes that PU.1 directly regulates are ultimately
crucial for understanding what this factor contributes to the T-
cell program. PU.1’s action as a positive regulator implies that
most of its direct target genes should be expressed in a pattern
concordant with its own expression. Indeed, PU.1-activated
target genes are preferentially expressed in the earliest stages of
T-cell development (examples shown in Figure 8). Many of them
are expressed also in at least one of the other contexts where PU.1
is active: in myeloid and dendritic lineage cells, in B lineage cells,
and particularly also in multipotent progenitor cells (Figure 8).
Among the smaller number of genes that appear to be directly
repressed by PU.1, most are specific for later stages of T-cell
development. These patterns reinforce the case for PU.1’s impact
in shaping the developmental timecourse of gene expression in
pro-T cells.
Developmentally potent transcription factors often transform
a cell’s identity by positively or negatively regulating the
expression of other transcription factors. As noted above, PU.1
can have this effect on early pro-T cells when it is overexpressed
and the cells switch to a non-T cell lineage program. But to what
extent does PU.1 control the expression of other transcription
factors within the T-cell program? It has become clear that the
progression of cells through T-cell commitment involves the
ordered downregulation of a substantial set of progenitor-specific
transcription factors, called “Phase 1” factors in this context,
concomitant with the upregulation of T-lineage affiliated factors
(34, 65, 84, 121, 122). PU.1 itself is downregulated at stage
when multiple other Phase 1 factors are downregulated, and a
key question is whether the withdrawal of positive PU.1 input
plays a role in the downregulation of these progenitor factors.
With respect to PU.1-mediated repression, some T-cell factors are
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FIGURE 8 | PU.1 globally regulates genes involved in multiple signaling and cell biological properties as well as other “phase 1” transcription factors across the stages
when PU.1 is expressed. Summary of normal expression patterns of representative groups of PU.1 regulated genes is shown, illustrated using the ImmGen (119)
(www.immgen.org) “My Gene Set” browser (http://rstats.immgen.org/MyGeneSet_New/index.html; Microarray V1). Natural levels of expression are shown in different
“Stem and Progenitor” cell sets (120) (under light blue bar) and in successive stages of “αβ T cell” development (121) (under purple bar), where the color scale
represents z score (warm colors, high expression; cold colors, low expression). Vertical line between “preT_DN2A_Th” and “preT_DN2B_Th” relates these stages to
the timing of commitment, when PU.1 levels decline. (A) Genes encoding transcription factors activated by PU.1 in multiple tests (58, 79, 85). (B) Representative
genes activated by PU.1 that encode tyrosine protein kinases, cytokine receptors, and G protein coupled receptors, from Table 1 [data from Ungerbäck et al. (85)].
(C) Genes activated by PU.1 that encode additional cell surface molecules, signaling receptors and adhesion molecules, from Table 1. (D) Genes repressed by PU.1,
encoding chemokine receptors and G-protein coupled receptors, from Table 1. Functional clusters used in this summary were as defined by DAVID Gene Functional
Classification tool (DAVID 6.8) (https://david.ncifcrf.gov/gene2gene.jsp).
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already upregulated while PU.1 is still highly expressed (GATA-
3, TCF-1, and the Notch target Hes1), but others are upregulated
only during the period when PU.1 declines (Bcl11b, Ets1, Lef1)
and could, in principle, have their expression timing affected
by PU.1 negative regulation. To what extent does PU.1 actually
control these gene expression patterns under the circumstances
of actual pro-T cell development, i.e. with strong Notch signaling
that prevents lineage switching?
Data from multiple studies show that PU.1 regulates a subset
of developmental control genes but is not alone in its actions.
Varied PU.1 gain and loss of function perturbations in the DN2-
DN3 stages show that PU.1 does provide positive input into a
discrete subset of Phase 1 regulatory genes, with Mef2c, Lmo2,
Bcl11a, and often also Hhex responding over a range of different
tests (58, 79, 80, 85). Consistent with an evolutionarily conserved
program in regulating these genes, the developmental expression
patterns of these genes and PU.1 (Spi1) in human pro-T cells
(Thy1—Thy4) are similar to their patterns in murine pro-T
cells (35). PU.1 is not uniquely responsible for the Phase 1
gene expression pattern, however, for other Phase 1 genes are
either unaffected or moderately inhibited by PU.1, as discussed
elsewhere (79, 123). Additional factors also probably collaborate
with PU.1 to fine-tune the responses of Mef2c and Lmo2, for
they are already declining by the end of ETP stage, multiple
cell cycles before DN2b stage when PU.1 itself declines (65,
67, 84, 121, 124) (Figure 8A). Thus, PU.1 is likely to be one
of several important positive regulators for these genes. PU.1
can indeed have negative regulatory effects on some of the T-
cell factors that are upregulated during commitment, but these
effects are greatly limited when the analysis is confined to
PU.1 activities within the T-cell program. Hes1, Tcf12 (HEB),
Ets1, and Lef1 are strongly affected in cells making a lineage
switch, but none of these are measurably repressed in cells
within the T-cell path. The cell cycle-regulatory locus E2f2,
which is also upregulated during commitment, is rare among
transcription factor coding genes in that it does appear to
be under active repression by PU.1 until the transition to
commitment. Thus, within the T-cell pathway, PU.1 has a specific
role in promoting maintenance of certain Phase 1 regulatory
genes before commitment, but little role in repressing T-cell
differentiation regulators directly.
PU.1 as a Choreographer of Thymocyte
Cell Biology
An important result from the genome-wide analysis of PU.1
target genes has been recognition of the major gene sets that
it does actively control in early pro-T cells. The number of
high confidence PU.1 target genes within the T-cell pathway
that code for transcription factor genes is low (Figure 8A).
In contrast, Gene Ontology and Pathway analyses as well as
simple gene lists reveal that PU.1 directly controls major systems
of cytokine receptors, chemokine receptors, tyrosine protein
kinases, G-protein receptor signaling molecules, and adhesion
or cytoskeletal system molecules (Table 2) (85). These directly
regulated targets, some of them studied little, if at all, in T-cell
development to date, might have a transformative impact on the
cell biology of the developing lymphocytes between the stages
when PU.1 is present and when it is shut off.
Potentially important clues to PU.1 roles are the prominence
among positively regulated PU.1 targets of genes encoding
specific cytokine receptors not yet studied in T-cell biology
(e.g., Pdgfrb); multiple protein tyrosine kinases (Btk, Syk, Hck,
Lyn); and G-protein coupled receptors (Ffar2, P2ry13, P2ry14)
and G protein signaling mediators (Gng2 and Rgs18); while
PU.1 represses other G protein signaling mediators (Gimap
and Gbp family members). In addition, PU.1 directly promotes
expression of cell surface molecules (CD33, CD34, CD44)
used as markers for stages in early T-cell development, but
which in vivo work to mediate environmental interactions,
and it drives expression of adhesion molecules (integrins and
Siglecs) as well as cytoskeletal components such as Coro2a
and Myo1f. Representative samples of the expression patterns
of such genes are shown in Figures 8B–D. The result is that
not only signaling capability but basic properties of adhesion,
motility and chemoresponsiveness of the cells can be under
PU.1 control in the early stages of T-cell development. While
these effects are not seen as direct transcriptional regulation of
other transcription factor coding loci, such target genes should
have numerous impacts on activation pathways in the cells
that induce transcriptional as well as migratory responses to
environmental signals.
The PU.1-high stages of thymocyte development are relatively
obscure in the context of the whole thymus, yet their accurate
regulation is crucial for establishment of immune system
homeostasis and avoidance of leukemia (125, 126). These stages
span multiple cell cycles in vivo and in vitro (33, 39, 67, 124).
However, cells in these stages are hard to visualize in the intact
thymus, as only a few cells per day are granted regulated entry
into the thymic antechamber (127), then migrate slowly through
the cortex, dispersing among a vast excess of more advanced T-
cell precursors, as they begin to differentiate toward commitment
(128). In postnatal mice, the entry point is thought to be formed
by specialized endothelial cells at the cortical/medullary border
of the thymus (129). Following an unknown triggering signal,
after a variable delay (125), the cells in each cohort then begin
to migrate centrifugally toward the outer thymic cortex, and cell
surface marker expression patterns imply that it is somewhere
midway in the course of this migration that the individual cells
undergo lineage commitment [reviewed by (60, 130)]. Because
of the extreme rarity of these very immature cells relative to
the later-stage thymocytes at any given time, they were almost
impossible to study in depth before the development of in vitro
culture systems (88), which have continued to be informative
to the present. However, the types of genes positively regulated
by PU.1 are overwhelmingly in categories likely to be involved
in mediating the interaction of the cells with very specific
environments. The tests of PU.1 function in these early pro-T
cells that have been done so far present the cells with Notch
ligands and cytokines, but could be fundamentally lacking in
other molecules presented by the normal thymic environment. It
will be of great interest to discover which anatomical subdomains
of the thymus actually supply the molecules that interact with
the potentially important receptors and adhesion molecules that
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TABLE 2 | Gene ontology and pathway classifications of genes regulated by PU.1
in pro-T cells.
(A) Genes upregulated by PU.1 in CD25+ cells with gain of function,
downregulated with sgRNA, relative to all genes expressed in cells












Reactive oxygen species metabolic
process (GO:0072593)
6.97 3.05E-02












Activation of immune response
(GO:0002253)
4.63 6.83E-03
Myeloid cell differentiation (GO:0030099) 4.55 3.80E-03
Positive regulation of protein secretion
(GO:0050714)
4.21 2.11E-02
Regulation of body fluid levels
(GO:0050878)
4.21 4.39E-02
Positive regulation of peptide secretion
(GO:0002793)
4.15 1.23E-02
Adaptive immune response (GO:0002250) 4.1 2.92E-02
Positive regulation of defense response
(GO:0031349)
4.07 1.59E-02
Regulation of MAP kinase activity
(GO:0043405)
3.95 2.32E-02
Defense response to other organism
(GO:0098542)
3.93 3.28E-03
Regulation of inflammatory response
(GO:0050727)
3.87 2.96E-02
Immune effector process (GO:0002252) 3.74 5.31E-04
Innate immune response (GO:0045087) 3.73 3.02E-04
(B) Genes downregulated by PU.1 in CD25+ cells with gain of
function, upregulated with sgRNA, relative to all genes expressed in
cells




Defense response to protozoan
(GO:0042832)
27.62 1.72E-02
Response to protozoan (GO:0001562) 25.11 2.57E-02
Cell activation (GO:0001775) 4.44 2.43E-03
Immune response (GO:0006955) 3.55 6.41E-03
Immune system process (GO:0002376) 2.86 2.26E-04




TABLE 2 | Continued
(C) Genes upregulated by PU.1 in CD44+ CD25- cells with gain of
function, downregulated with sgRNA, relative to all genes expressed
in cells






Regulation of coagulation (GO:0050818) 8.85 5.55E-03
Regulation of blood coagulation
(GO:0030193)
8.58 2.49E-02
Regulation of hemostasis (GO:1900046) 8.36 2.98E-02






Regulated exocytosis (GO:0045055) 5.93 4.94E-02
Defense response to bacterium
(GO:0042742)
5.16 5.18E-03
Positive regulation of stress-activated
protein kinase signaling cascade
(GO:0070304)
5.04 2.95E-03
Inflammatory response (GO:0006954) 4.98 5.37E-09
Positive regulation of stress-activated
MAPK cascade (GO:0032874)
4.77 1.29E-02
Regulation of body fluid levels
(GO:0050878)
4.62 1.78E-04
Leukocyte activation involved in immune
response (GO:0002366)
4.53 4.90E-02
Positive regulation of defense response
(GO:0031349)
4.51 2.71E-05
Positive regulation of MAP kinase activity
(GO:0043406)
4.42 6.86E-03
Exocytosis (GO:0006887) 4.29 4.18E-02
Regulation of inflammatory response
(GO:0050727)
4.29 6.51E-05
Positive regulation of response to external
stimulus (GO:0032103)
4.09 2.38E-03
Regulation of MAP kinase activity
(GO:0043405)
4.01 8.19E-04
Activation of immune response
(GO:0002253)
3.85 3.77E-02




Defense response to other organism
(GO:0098542)
3.7 8.48E-04
(D) Genes downregulated by PU.1 in CD44+ CD25- cells with gain of
function, upregulated with sgRNA, relative to all genes expressed in
cells




T cell activation (GO:0042110) 4.77 3.82E-04
Lymphocyte activation (GO:0046649) 4.51 7.36E-07
Cell-cell adhesion (GO:0098609) 4.22 9.44E-03
Cell activation (GO:0001775) 4.19 1.78E-08
Lymphocyte differentiation (GO:0030098) 4.18 1.07E-02
Leukocyte activation (GO:0045321) 4.12 1.14E-06
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TABLE 2 | Continued
(D) Genes downregulated by PU.1 in CD44+ CD25- cells with gain of
function, upregulated with sgRNA, relative to all genes expressed in
cells




Leukocyte differentiation (GO:0002521) 3.52 2.88E-02
Positive regulation of cell adhesion
(GO:0045785)
3.45 2.10E-02
Regulation of defense response
(GO:0031347)
3.11 1.15E-02
Regulation of cell adhesion (GO:0030155) 3.09 1.01E-03
Biological adhesion (GO:0022610) 2.9 2.29E-02
Positive regulation of transcription by RNA
polymerase II (GO:0045944)
2.46 2.21E-03
Regulation of immune system process
(GO:0002682)
2.35 3.85E-03
Immune system process (GO:0002376) 2.3 3.44E-05
Regulation of multicellular organismal
process (GO:0051239)
1.74 3.15E-02
Positive regulation of biological process
(GO:0048518)
1.48 6.54E-03
The table shows PANTHER Overrepresentation Analysis (www.geneontology.org) of
categories of genes upregulated or downregulated by PU.1. In each case, responding
genes were defined by reciprocal changes in expression in PU.1 gain of function and
PU.1 loss of function experiments in the DN2a-DN2b interval as in Table 1. Whereas
Table 1 shows the three-way intersection of genes affected in loss of function, in gain
of function for cells remaining CD25+, and in gain of function for cells becoming CD25−
CD44+, here the effects of the gain of function perturbations were separated to allow
comparison of results from cells remaining in the T-cell pathway (CD25+) with results
from cells likely deviating toward another fate (CD44+). Database for comparison was all
genes expressed in control DN2 cells. Statistical results shown are for a Fisher Test with
Bonferroni correction for multiple sample testing. The PANTHER Overrepresentation Test
version was released 2018-10-10 using the GOOntology database released 2018-10-08.
For PU.1 activated genes, only the top 21 enriched categories are shown.
PU.1 enables the cells to express, and what responses they trigger
in these earliest T-cell precursors.
PU.1 AND THE REGULATION OF
LYMPHOID DEVELOPMENT IN ONTOGENY
The studies reviewed throughout this paper have characterized
the roles of PU.1 in T-cell development in the young postnatal
mouse or in late fetal life. Very recent work has now placed these
roles of PU.1 into a wider developmental perspective.
The cells used for in vitro differentiation as well as in vivo
analysis in the work reviewed above have all been derived from
waves of hematopoiesis that begin with definitive hematopoietic
stem cells, which first appear in the mouse fetal liver by about
day 11.5 of gestation and may be followed by additional stem-
cell waves through the end of gestation (day 20) (131). Thus,
postnatal thymocytes and any in vitro differentiation cultures
seeded with cells from bone marrow or fetal liver from E15
onward are likely to come from true stem cell origins. However,
there are earlier hematopoietic progenitors in the embryo that
derive from yolk sac, cells with varied developmental potentials
but without true stem-cell self-renewal. The first wave of T cell
development in the fetus is now thought to arise from these non-
stem-cell precursors in the yolk sac (132, 133). It has long been
recognized that the earliest fetal thymocytes are different from
later waves of developing thymocytes in terms of their abilities
to generate particular classes of TCRγδ cells (134) and in terms
of their extremely fast differentiation kinetics, both in vivo and
in fetal thymic organ culture or stromal coculture systems (104,
133, 135). This is now understood to be intrinsically programmed
(136) and due to an altered pathway of differentiation in the
first-wave cells, which results in T-cell lineage commitment even
before entry into the thymus (137–139).
Remarkable differences have been reported between genetic
requirements for T cell development derived from earlier and
later waves of prethymic progenitors. For example, the crucial
T-lineage transcription factor TCF-1, which plays roles in
numerous phases of thymocyte development (95, 140–145), is
essential to maintain adult T-cell production but dispensable in
fetal and early postnatal T cell development (146). A wave of fetal
T cell development can also, apparently, be generated without
PU.1 (71). In the case of PU.1, the change in its role occurs
within fetal life, and this has now been sharply situated in the
transition from precociously committed “first-wave” precursors
to precursors that enter the thymus while still multipotent (147).
ETPs derived from these precursors naturally express lower levels
of PU.1 than adult ETPs, but they are almost unchanged in
their ability to generate early fetal T cells when the level of
PU.1 is reduced still further (∼5 fold) by deletion of the major
upstream regulatory element of PU.1 (147). In contrast, the
same five-fold diminished level of PU.1 sharply degrades the
ability of later fetal hematopoietic stem and progenitor cells to
generate T cells at all, in vivo or in vitro, with functional and
phenotypic defects evident in the mutants in both multipotent
progenitors and newly-entered intrathymic ETPs, as early as in
the late fetus. This difference in PU.1 dependence accompanies a
subtly different T-cell developmental program. Gene expression
differences have been noted between the normal first-wave fetal
and adult pro-T cells in the thymus at corresponding stages which
indicate that the fetal program drives accelerated development
(148, 149). Montecino-Rodriguez et al. point out that these
differences conspicuously include reduced initial expression of
multiple PU.1-dependent genes in the fetal cells (147). Thus,
not only is the first-wave fetal program less dependent on
PU.1, but also it may rely on relatively low PU.1 activity for
its very distinctiveness. These results therefore support a role
for PU.1 in delaying differentiation in order to allow more
extended proliferation before commitment, showing how the
importance of this role is ontogenically scaled to the needs of the
developing organism.
The first-wave precursor cells, also uniquely, enter the thymus
by a different route than all subsequent waves. Instead of entering
through the blood vessels near the cortical-medullary junction,
these early cells migrate through cervical-region mesenchyme
to the thymic anlage before it is vascularized. The thymus does
not yet have a capsule to present a physical barrier, and the
first-wave cells enter directly through the future outer cortex.
Thus, they may not use the same interactions with basement
membrane, endothelial cells, or chemokine gradients as any
future wave of thymic precursors. Not only are these cells
intrinsically programmed to cut short the stages supported
by PU.1-dependent transcriptional regulators, but also they
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can dispense with many of the cell biological tools that PU.1
may provide to later-wave successors to navigate the adult or
late-fetal thymus.
CONCLUSIONS AND FUTURE QUESTIONS
PU.1 is a broad regulator of the properties of the cells that first
enter the thymus, and it helps to determine their proliferation
and rate of progression to commitment after they arrive. While
dysregulated PU.1 can cause trans-differentiation to myeloid or
dendritic-cell fates, endogenous PU.1 normally plays a protracted
role within early T-cell development. Its target genes are
occasionally repressed but mostly activated by PU.1 binding, and
they confer on the cells distinctive stage-specific transcription
factor expression patterns as well as a rich array of stage-specific
cell biological features that await proper functional analysis.
This positive regulatory role is one result of PU.1’s strong
pattern of binding across the genome, its prominent occupancy
of open chromatin sites, and the evidence that it helps to
maintain the open chromatin states at bound regulatory sites
as long as it is expressed. The number of genes that respond
quickly to changes in PU.1 activity may only account for a
minority of all the genomic sites where PU.1 is found engaged;
at other sites, its role could be structural or redundant with
other factors. However, it is clear that PU.1 also affects the
activity of certain genes that it does not bind to directly, via
creating preferential interaction sites for other factors that can
deplete the regulatory elements of those factors’ alternative target
genes. Through chromatin state placeholding and “coregulator
theft” as well as through its own direct transcriptional activities,
PU.1 pervades the regulatory state of early T cells as long as it
is expressed.
This phase comes to an end when other transcription factors
finally accumulate to the point where they can shut PU.1 off. The
best current candidates for this silencing activity include GATA-
3 (104, 105), TCF-1 or LEF-1 (37), and especially Runx1 (80,
150–152), probably working in a dose-dependent combination,
although the mechanism through which they finally achieve the
ability to repress PU.1 has not yet been reported. Importantly, the
duration of the PU.1 activity phase is regulated to vary among
different ontogenic waves of T cell development. It probably
extends for over 10 days for the thymocytes in young adult mice
(153), where it is crucial for successful T-cell generation (2, 147).
In contrast, for many first-wave fetal thymocytes it may last only
a day or two, and is mostly or entirely dispensable (71, 147).
This indicates that the specific constellation of functions that
PU.1 serves in T-cell development is a module within the larger
T-cell developmental program that can be deployed optionally
to serve a particular role. Perhaps it is more important for
scaling the population dynamics of T-cell production as the
animal finishes gestation and grows, or for promoting accurate
migration through distinct thymic microenvironments, than for
making T cell precursors per se.
The pioneering role of PU.1 on the genome raises fascinating
questions for future study that connect mechanism with
developmental lineage selection. Hematopoietic progenitors
express PU.1 before they enter the thymus, but the pattern of its
occupancy is not well defined at that stage, so the onset of PU.1’s
pioneering activity in precursors that will eventually generate
T cells is not easy to study. The mechanisms discussed in this
review show that it establishes a pre-pattern that can influence
the binding of the other transcription factors expressed in the
cell throughout multiple cell cycles in the thymus. It is not clear,
though, how this particular pre-pattern is set, to be distinguished
from PU.1 binding patterns in B cells and myeloid cells (84).
The question could be linked with the deeper mystery of the
factors involved in designating some multipotent precursors to
enter the thymus in the first place, as opposed to remaining in
the bone marrow for programming into B cells, natural killer
cells, or innate lymphoid cells. So far the innate lymphoid cell
developmental program in particular appears to resemble the
intrathymic T-cell program in many respects (154–157), enough
to raise the question of what makes T-cell precursors wait to
activate genes like Tcf7 and Gata3 until they reach the thymus.
Is PU.1 part of the answer? The system-wide impact of PU.1 on
other factors suggests that in scenarios where PU.1 is absent, the
same T-cell transcription factors might initially choose different
binding sites. Indeed, pro-T cells that have PU.1 acutely deleted
at an early stage do not only differentiate faster along the T
lineage; they also tend to shift to a natural killer-like program
more readily than controls (79). Thus, activity of PU.1 may be
important, also, to block certain alternative differentiation paths
for pro-T cells. In the end, is T-cell lineage fidelity itself partly a
legacy of PU.1’s transient role?
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